Precision BioSciences, Inc.

DB:PBS0 Stock Report

Market Cap: €47.9m

Precision BioSciences Valuation

Is PBS0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PBS0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PBS0 (€6.3) is trading below our estimate of fair value (€111.76)

Significantly Below Fair Value: PBS0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PBS0?

Key metric: As PBS0 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PBS0. This is calculated by dividing PBS0's market cap by their current earnings.
What is PBS0's PE Ratio?
PE Ratio4.9x
EarningsUS$11.48m
Market CapUS$49.86m

Price to Earnings Ratio vs Peers

How does PBS0's PE Ratio compare to its peers?

The above table shows the PE ratio for PBS0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average10.5x
2INV 2invest
12.7xn/a€63.8m
FYB Formycon
12.9x31.5%€827.2m
BIO3 Biotest
15.8x29.3%€1.4b
ECX Epigenomics
0.4xn/a€875.2k
PBS0 Precision BioSciences
4.9x-41.0%€49.9m

Price-To-Earnings vs Peers: PBS0 is good value based on its Price-To-Earnings Ratio (4.9x) compared to the peer average (10.5x).

Price to Earnings Ratio vs Industry

How does PBS0's PE Ratio compare vs other companies in the European Biotechs Industry?

6 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.26.9x43.0%
PBS0 Precision BioSciences
 4.9x-41.0%US$49.86m
PBS0 4.9xIndustry Avg. 26.9xNo. of Companies5PE020406080100+
6 CompaniesEstimated GrowthMarket Cap
Industry Avg.26.9x43.0%
PBS0 Precision BioSciences
 4.9x-41.0%US$49.86m
No more companies

Price-To-Earnings vs Industry: PBS0 is good value based on its Price-To-Earnings Ratio (4.9x) compared to the European Biotechs industry average (26.9x).

Price to Earnings Ratio vs Fair Ratio

What is PBS0's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PBS0 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.9x
Fair PE Ratio4.6x

Price-To-Earnings vs Fair Ratio: PBS0 is expensive based on its Price-To-Earnings Ratio (4.9x) compared to the estimated Fair Price-To-Earnings Ratio (4.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PBS0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€6.30
€33.76
+435.8%
42.1%€56.65€17.94n/a4
Nov ’25€8.00
€33.12
+313.9%
42.1%€55.58€17.60n/a4
Oct ’25€7.75
€30.33
+291.4%
42.0%€54.16€17.15n/a5
Sep ’25€9.65
€30.59
+217.0%
39.3%€55.62€17.61n/a6
Aug ’25€9.20
€30.59
+232.5%
39.3%€55.62€17.61n/a6
Jul ’25€9.00
€30.59
+239.9%
39.3%€55.62€17.61n/a6
Jun ’25€10.80
€30.59
+183.3%
39.3%€55.62€17.61n/a6
May ’25€9.05
€30.91
+241.6%
39.3%€56.21€17.80n/a6
Apr ’25€12.20
€34.68
+184.3%
36.3%€55.86€23.28n/a4
Mar ’25€11.66
€74.57
+539.5%
17.7%€83.89€55.93n/a3
Feb ’25€9.30
€73.59
+691.3%
17.7%€82.79€55.19n/a3
Jan ’25€9.84
€74.70
+659.2%
17.7%€84.04€56.03n/a3
Dec ’24€9.60
€74.70
+678.2%
17.7%€84.04€56.03n/a3
Nov ’24€7.98
€73.30
+818.5%
38.1%€112.76€39.47€8.004
Oct ’24€9.12
€73.30
+703.7%
38.1%€112.76€39.47€7.754
Sep ’24€12.60
€75.42
+498.5%
52.0%€137.96€27.59€9.656
Aug ’24€15.45
€83.45
+440.2%
54.1%€136.07€27.21€9.206
Jul ’24€14.34
€181.50
+1,165.7%
74.8%€462.83€27.23€9.006
Jun ’24€20.70
€181.50
+776.8%
74.8%€462.83€27.23€10.806
May ’24€22.20
€181.50
+717.6%
74.8%€462.83€27.23€9.056
Apr ’24€20.08
€167.76
+735.6%
81.6%€475.32€27.96€12.207
Mar ’24€31.56
€185.37
+487.4%
73.3%€469.35€27.61€11.667
Feb ’24€32.30
€185.37
+474.0%
73.3%€469.35€27.61€9.307
Jan ’24€27.99
€194.99
+596.7%
69.6%€500.36€29.43€9.848
Dec ’23€38.79
€194.99
+402.7%
69.6%€500.36€29.43€9.608
Nov ’23€43.92
€242.48
+452.1%
66.0%€587.82€58.78€7.988

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Merck

US$246.5b

Operates as a healthcare company worldwide.

6MK

US$93.40

7D

0.3%

1Y

-0.4%